1. In Vivo

Human Genome's Risk-Management Math

Human Genome Sciences believes its lead in genomics--it claims to have nearly all human genes in its database--is already letting it beat the biotech odds in the clinic by allowing it to pick better proteins to develop and then follow them up with a virtually inexhaustible source of new candidates. Skeptics don't like the company's arithmetic.

by Roger Longman

As a group, all genomics companies promise investors a lower risk opportunity than they could get investing in most previous product-oriented biotech companies. Most saw, and still see, themselves as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo